Ground Swell Capital LLC Invests $377,000 in Novo Nordisk A/S (NYSE:NVO)

Ground Swell Capital LLC acquired a new stake in Novo Nordisk A/S (NYSE:NVO) during the 3rd quarter, Holdings Channel reports. The fund acquired 3,164 shares of the company’s stock, valued at approximately $377,000.

Other institutional investors have also recently bought and sold shares of the company. GQG Partners LLC increased its stake in shares of Novo Nordisk A/S by 654.6% in the first quarter. GQG Partners LLC now owns 3,633,064 shares of the company’s stock valued at $466,485,000 after buying an additional 3,151,584 shares during the period. International Assets Investment Management LLC lifted its stake in shares of Novo Nordisk A/S by 10,608.4% in the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after acquiring an additional 1,796,635 shares during the period. DSM Capital Partners LLC boosted its holdings in Novo Nordisk A/S by 257,816.0% in the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after acquiring an additional 1,593,303 shares during the last quarter. Acadian Asset Management LLC increased its position in Novo Nordisk A/S by 1,300.8% during the 1st quarter. Acadian Asset Management LLC now owns 1,244,128 shares of the company’s stock valued at $159,703,000 after purchasing an additional 1,155,313 shares during the period. Finally, Mediolanum International Funds Ltd bought a new position in Novo Nordisk A/S during the 3rd quarter worth approximately $98,765,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday, October 10th. BMO Capital Markets cut their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. Finally, StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Stock Down 0.0 %

Shares of NYSE NVO opened at $111.94 on Monday. The company has a debt-to-equity ratio of 0.46, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 1 year low of $94.73 and a 1 year high of $148.15. The stock has a market capitalization of $502.33 billion, a P/E ratio of 38.34, a P/E/G ratio of 1.46 and a beta of 0.43. The company has a 50-day moving average price of $124.25 and a 200-day moving average price of $130.94.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). The company had revenue of $9.82 billion for the quarter, compared to the consensus estimate of $9.91 billion. Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. On average, equities research analysts forecast that Novo Nordisk A/S will post 3.01 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 16th were issued a $0.5126 dividend. The ex-dividend date was Friday, August 16th. This represents a dividend yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio is currently 24.66%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.